



A whole new MAGNAtude of performance.

MAGNA

Carpentier-Edwards PERIMOUNT


MAGNA

Pericardial Aortic Bioprosthesis




Edwards
LIFESCIENCES

THE WORLD PREMIERE OF



True supra-annular design enables optimal upsizing for improved performance.



MAGNA

nothing else measures up



A New MAGNAtude

of Hemodynamic Performance

- True supra-annular design
- Enables optimal upsizing for up to 23% greater EOA

A New MAGNAtude

of Tissue Treatment

- State-of-the-art tissue treatment eliminates up to 98% of calcium binding sites^{1*}
- Anticalcification agent that results in the lowest levels of calcium among all tissue valves in a comparative animal study^{2*}

A New MAGNAtude

of Durability

- Designed on the foundation of the PERIMOUNT pericardial valve's unparalleled 20-year durability data³

References:

1. Process Optimization Baseline Study Final Report RD597. Data on file at Edwards Lifesciences, 2003.
2. Flameng, et al. A New Approach for *In Vitro* Testing of Tissue Valves. Presentation at Hilton Head Heart Valve Work Shop. Mar 6-10, 2002.
3. Carpentier-Edwards PERIMOUNT Pericardial Bioprosthesis 20-Year Results. Data on file at Edwards Lifesciences, 2003.

* No clinical data are available which evaluate the long-term impact of the Edwards tissue treatment in patients.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information.

Edwards Lifesciences, Edwards, the stylized E logo, Magna and PERIMOUNT Magna are trademarks of Edwards Lifesciences Corporation. Carpentier-Edwards and PERIMOUNT are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark office.

©2004 Edwards Lifesciences LLC
All rights reserved. AR00381



Edwards Lifesciences